Producción CyT
Congreso
Autoría
Oglio, R
;
Rossich, L
;
Salvarredi, L
;
Pisarev, M
;
Juvenal, G
;
THOMASZ, LISA
Fecha
2018
Editorial y Lugar de Edición
Medicina
Resumen
Información suministrada por el agente en
SIGEVA
BACKGROUND:Overexpression of NADPH oxidase isoform 4 (NOX4) has been implicated in promoting cell survival, migration and invasion in many cancers. Anaplastic thyroid cancer (ATC) is one of the most lethal human malignancies. In the present study, we studied the effect of suppressing NOX4 by RNA silencing on the survival and migration on the ATC cell line, 8505C.METHODS:Small interfering RNA (siRNA) constructs targeting NOX4 were validated and used to develop clonal derivatives of the ATC cell ...
BACKGROUND:Overexpression of NADPH oxidase isoform 4 (NOX4) has been implicated in promoting cell survival, migration and invasion in many cancers. Anaplastic thyroid cancer (ATC) is one of the most lethal human malignancies. In the present study, we studied the effect of suppressing NOX4 by RNA silencing on the survival and migration on the ATC cell line, 8505C.METHODS:Small interfering RNA (siRNA) constructs targeting NOX4 were validated and used to develop clonal derivatives of the ATC cell line, 8505C. Cell viability was measured by MTT (thiazolyl blue tetrazolium bromide) assay. The wound healing assay was used to determine the migration of cells in culture. The expression of mesenchymal markers such as vimentin and E-cadherin was detected by Western blot. Transforming growth factor β1 (TGF-β1), FOXO1 and FOXO3 expression was determined by quantitative RT-PCRRESULTS:Targeting NOX4 expression in 8505C cells caused a 30 % decrease in migration and Western Blot analysis shows an increase of E-cadherin expression. However the cell viability has not changed. NOX4 siRNAs decreased mRNA levels of TGF-β1 (30%) and increased FOXO1 (20%) and FOXO3 (90%) mRNA expression.CONCLUSION:Targeting NOX4 in combination with other tumor-targeted drugs could be enhances the anticancer therapies in ATC.
Ver más
Ver menos
Palabras Clave
CANCERNOX-4IODINETHYROID